Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors.

abstract：:The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

journal_title：Bone marrow transplantation

authors： Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

更新日期：2010-01-01 00:00:00

abstract：:ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored ...

journal_title：Bone marrow transplantation

authors： Heal JM,Liesveld JL,Phillips GL,Blumberg N

更新日期：2005-11-01 00:00:00

abstract：:Infection with human cytomegalovirus (HCMV) after allogeneic bone marrow transplantation (BMT) was studied in 12 HCMV seronegative recipients of marrow from seropositive donors by weekly monitoring of cultures, expression of HCMV antigenemia (pp65) in granulocytes, polymerase chain reaction (PCR) on HCMV-DNA in granul...

journal_title：Bone marrow transplantation

authors： de Gast GC,Boland GJ,Vlieger AM,de Weger RA,Verdonck LF,Zwaan FE,Jiwa NM

更新日期：1992-04-01 00:00:00

abstract：:A questionnaire comprised of a series of clinical vignettes illustrating potential difficulties in diagnosis, grading and treatment of chronic graft-versus-host disease (GVHD) was completed by 65 bone marrow transplant physicians from 51 transplant centers worldwide. The concordance index (CI) for responses to each qu...

journal_title：Bone marrow transplantation

authors： Atkinson K,Horowitz MM,Gale RP,Lee MB,Rimm AA,Bortin MM

更新日期：1989-05-01 00:00:00

abstract：:Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI +/- fludarabine and post...

journal_title：Bone marrow transplantation

authors： Frère P,Baron F,Bonnet C,Hafraoui K,Pereira M,Willems E,Fillet G,Beguin Y

更新日期：2006-02-01 00:00:00

abstract：:One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 microg/kg/day (range 3-16) for a median of 6 days...

journal_title：Bone marrow transplantation

authors： Cavallaro AM,Lilleby K,Majolino I,Storb R,Appelbaum FR,Rowley SD,Bensinger WI

更新日期：2000-01-01 00:00:00

abstract：:Paecilomyces varioti, a fungus resembling penicillium spp, has been described in conjunction with impaired host defence or foreign body implants. We report a case of Paecilomyces varioti catheter-related fungemia that occurred during neutropenia in an allogeneic BMT patient receiving antifungal prophylaxis with flucon...

journal_title：Bone marrow transplantation

authors： Shing MM,Ip M,Li CK,Chik KW,Yuen PM

更新日期：1996-02-01 00:00:00

abstract：:The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

journal_title：Bone marrow transplantation

authors： Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

更新日期：1994-11-01 00:00:00

abstract：:Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism...

journal_title：Bone marrow transplantation

authors： Swaminathan VV,Uppuluri R,Patel S,Sivashankaran M,Ravichandran N,Ramanan KM,Ramakrishnan B,Vaidhyanathan L,Raj R

更新日期：2019-11-01 00:00:00

abstract：:Gastrointestinal (GI) GVHD after allo-SCT is diagnosed on the basis of symptoms and findings in endoscopic mucosal biopsy specimens. However, GI symptoms often persist despite treatment and whether a second endoscopy may be helpful in determining the most suitable therapy is not established. We identified 31 patients ...

journal_title：Bone marrow transplantation

authors： Martínez C,Rosales M,Calvo X,Cuatrecasas M,Rodriguez-Carunchio L,Llach J,Fernández-Avilés F,Rosiñol L,Rovira M,Carreras E,Urbano-Ispízua A

更新日期：2012-05-01 00:00:00

abstract：:The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

journal_title：Bone marrow transplantation

authors： Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

更新日期：2014-02-01 00:00:00

abstract：:HLA-DP typing is not routinely performed before allogeneic BMT. This highly polymorphic class II locus is implicated in immune response and DP molecules may act as transplantation antigens. HLA-DP incompatibilities contribute to MCL. In BMT performed between siblings, HLA-DP mismatches are rare and the role of such in...

journal_title：Bone marrow transplantation

authors： Moreau P,Cesbron A

更新日期：1994-06-01 00:00:00

abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

journal_title：Bone marrow transplantation

authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

更新日期：2013-03-01 00:00:00

abstract：:Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progression from myelodyspl...

journal_title：Bone marrow transplantation

authors： Stein AS,O'Donnell MR,Synold TW,Dagis AC,Tsirunyan A,Nademanee AP,Parker PM,Pullarkat VA,Snyder DS,Spielberger RT,Wong JY,Alvarnas JC,Thomas SH,Forman SJ

更新日期：2011-09-01 00:00:00

abstract：:Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in c...

journal_title：Bone marrow transplantation

authors： Doney K,Buckner CD,Fisher L,Petersen FB,Sanders J,Appelbaum FR,Anasetti C,Badger C,Bensinger W,Deeg HJ

更新日期：1993-10-01 00:00:00

abstract：:A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

journal_title：Bone marrow transplantation

authors： Khan AM,Yamase H,Tutschka PJ,Bilgrami S

更新日期：1997-05-01 00:00:00

abstract：:Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy. Oral complications may lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier ...

journal_title：Bone marrow transplantation

authors： Karthaus M,Rosenthal C,Ganser A

更新日期：1999-11-01 00:00:00

abstract：:Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple mye...

journal_title：Bone marrow transplantation

authors： Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m(2) and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD ...

journal_title：Bone marrow transplantation

authors： Christopoulos P,Schmoor C,Waterhouse M,Marks R,Wäsch R,Bertz H,Finke J

更新日期：2013-07-01 00:00:00

abstract：:Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections predominate. Catheter-related infections and associated risk factors in 392 patients participating in a randomized adjuvant breast cancer trial and assigned to receive...

journal_title：Bone marrow transplantation

authors： Nieboer P,de Vries EG,Mulder NH,Rodenhuis S,Bontenbal M,van der Wall E,van Hoesel QG,Smit WM,Hupperets P,Voest EE,Nooij MA,Boezen HM,van der Graaf WT

更新日期：2008-10-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:Autologous HCT patients often have poor oral intake for 2-4 weeks post transplant. To compare outcomes between patients provided prophylactic total parenteral nutrition (TPN) or an oral diet (OD), 55 well nourished breast cancer/ hematopoietic cell transplantation (HCT) patients were randomized to TPN (n=27), beginnin...

journal_title：Bone marrow transplantation

authors： Roberts S,Miller J,Pineiro L,Jennings L

更新日期：2003-10-01 00:00:00

abstract：:A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed ...

journal_title：Bone marrow transplantation

authors： Sevilla J,González-Vicent M,Madero L,Díaz MA

更新日期：2001-07-01 00:00:00

abstract：:An unblinded, historical controlled study of 49 bone marrow transplant (BMT) patients was carried out in our institution to assess the effect of oral pentoxifylline (PTX) on BMT regimen related toxicity (RRT). Twenty-eight consecutively treated BMT patients (17 allogeneic, 11 autologous) were entered into the PTX trea...

journal_title：Bone marrow transplantation

authors： van der Jagt RH,Pari G,McDiarmid SA,Boisvert DM,Huebsch LB

更新日期：1994-02-01 00:00:00

abstract：:The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a...

journal_title：Bone marrow transplantation

authors： Cupit MC,Duncan C,Savani BN,Hashmi SK

更新日期：2016-02-01 00:00:00

abstract：:Patients with leukemia relapsing after allogeneic hematopoietic SCT have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsing after a myeloablative HLA-matched sibling T c...

journal_title：Bone marrow transplantation

authors： McIver ZA,Yin F,Hughes T,Battiwalla M,Ito S,Koklanaris E,Haggerty J,Hensel NF,Barrett AJ

更新日期：2013-09-01 00:00:00

abstract：:Multiple sclerosis (MS) is considered an inflammatory autoimmune disorder. Approved immunotherapies are only moderately effective in reducing disease exacerbations and brain inflammation in a subset of patients. Autologous hematopoietic stem cell transplantation (HSCT) has emerged in recent years as the first opportun...

journal_title：Bone marrow transplantation

authors： Muraro PA,Martin R

更新日期：2003-08-01 00:00:00

abstract：:Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

journal_title：Bone marrow transplantation

authors： Bhagat R,Sporn TA,Long GD,Folz RJ

更新日期：2001-05-01 00:00:00

abstract：:Nine patients with haematological malignancy relapsed 3-32 months after receiving cyclophosphamide 120 mg/kg, 12-14 Gy fractionated total body irradiation and an HLA-identical sibling bone marrow transplant. They were reconditioned with melphalan 180-220 mg/m2 and retransplanted using the same donor and the same cyclo...

journal_title：Bone marrow transplantation

authors： Atkinson K,Biggs J,Concannon A,Dodds A,Dale B,Norman J

更新日期：1986-12-01 00:00:00

abstract：:We retrospectively compared the incidence of acute graft-versus-host disease (GVHD) before and after September 1999, when we changed the mode of cyclosporine A (CsA) administration from twice-daily infusions (TD) (n=58) to continuous infusion (CIF) (n=71). The incidence of grade II-IV acute GVHD in the CIF group (56%)...

journal_title：Bone marrow transplantation

authors： Ogawa N,Kanda Y,Matsubara M,Asano Y,Nakagawa M,Sakata-Yanagimoto M,Kandabashi K,Izutsu K,Imai Y,Hangaishi A,Kurokawa M,Tsujino S,Ogawa S,Aoki K,Chiba S,Motokura T,Hirai H

更新日期：2004-03-01 00:00:00